Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03319537 · ClinicalTrials.gov registry record · Phase 1
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03319537: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03319537 is a Phase 1 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03319537, a Phase 1 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.
Interventions
- DRUG pevonedistat
- DRUG Pemetrexed and cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03319537
The ClinicalTrials.gov registry entry for NCT03319537 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pevonedistat is the first listed.
NCT03319537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03319537 about?
NCT03319537 is a clinical study titled "Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma". The purpose of this study is to test any good and bad effects of activity pevonedistat taken alone, and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin.
What is the current status of trial NCT03319537?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-10-05. Estimated completion is 2023-06-05.
What interventions are being tested in trial NCT03319537?
The interventions under investigation include: pevonedistat (DRUG), Pemetrexed and cisplatin (DRUG).
Who is sponsoring clinical trial NCT03319537?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.